Probiodrug AG to
Publish First Half 2017 Results on 31 August 2017
HALLE (SAALE),
Germany, 24 August 2017 - Probiodrug AG (Euronext
Amsterdam: PBD), a biopharmaceutical company developing novel
therapeutic solutions to treat Alzheimer's disease (AD), will
publish its results for the first six months of 2017 on Thursday,
31 August 2017. The company will host a conference call open to the
public on 31 August 2017 at 15:00 Central European Summer Time
(CEST).
The results of the first six
months of 2017 will be available for download on the company
website
(http://www.probiodrug.de/investors/reports-and-presentations/).
###
For more
information please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume
Brophy
Conor Griffin, Alexander Protsenko, Jonothan Blackbourn
Tel: +44 (0) 20 7862 6381
Email: probiodrug@humebrophy.com
The Trout
Group
Tricia Truehart
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com
MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20
Email: probiodrug@mc-services.eu
Notes to
Editors:
About Probiodrug AG
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext
Amsterdam: PBD) is a biopharmaceutical company focused on the
development of new therapeutic products for the treatment of
Alzheimer's disease (AD). Probiodrug has identified a new
therapeutic concept linked to disease initiation and progression.
The development approaches are targeting a key neuro/synaptotoxic
component of the pathology, pyro-Glutamate-Abeta (pGlu-Abeta, N3pG)
as a therapeutic strategy.
Probiodrug's lead product
candidate, PQ912, is a highly specific and potent inhibitor of
Glutaminyl Cyclase (QC), which has shown therapeutic effects
in AD animal models. A Phase 1 study in healthy young and
elderly volunteers revealed a dose dependent exposure and
showed good safety and tolerability up to the highest dose showing
>90% target occupancy in the spinal fluid. In June 2017
Probiodrug announced top-line data of the Phase 2a SAPHIR trial of
its lead candidate (Probiodrug announces encouraging results of the
Phase 2a SAPHIR Study ). The positive effects seen on secondary
exploratory efficacy markers are strongly supporting (a) the
hypothesis of pGlu-Abeta being synaptotoxic and (b) the therapeutic
concept pursued by Probiodrug. The study revealed a positive
benefit risk ratio of PQ912 and provides important guidance how to
move forward in the development of PQ912 as a disease-modifying
drug for AD. Altogether, the results make the program highly
attractive for further development.
Complementary to the small
molecule PQ912 inhibiting the formation of the synaptotoxic agent
pGlu-Abeta, the company is developing PBD-C06, an
anti-pGlu-Abeta-specific monoclonal antibody.
The Company has medical use and composition of matter patents
related to the inhibition of QC and anti-pGlu-Abeta-specific
monoclonal antibodies, and has, in the Company's view, a leading
position in this field of research.
Founded in 1997 by Hans-Ulrich
Demuth and Konrad Glund, the company successfully developed a novel
therapeutic concept for diabetes - the DP4 inhibitors - which
provided the basis for a novel class of antidiabetics - the
gliptins. Its core capabilities are based on its long-standing
expertise in the elucidation of the structure and function of
enzymes involved in the modification of proteins and peptides,
which play a central role in pathological conditions.
Today, Probiodrug aims to become a
leading company in the development of AD treatments and to thereby
provide a better life for Alzheimer's disease patients.
www.probiodrug.de
About Alzheimer's
disease
Alzheimer's disease is a neurological disorder, which is the most
common form of dementia, and ultimately leads to death. Because
Alzheimer's disease cannot be cured and is degenerative, the
affected patients must increasingly rely on others for assistance.
Today, 47 million people live with dementia worldwide, and this
number is projected to treble to more than 131 million by 2050, as
populations age. Dementia also has a huge economic impact.
Alzheimer's has an estimated, global societal cost of US$ 818
billion, and it will become a trillion dollar disease by 2018.
(World Alzheimer Report 2016).
Forward Looking
Statements
Information set forth in this press release
contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of Probiodrug AG as of the date of
this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.